News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


LCT Parkinson’s trial resumes patient recruitment

LCT Parkinson’s trial resumes patient recruitment

23 June 2014 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited today announced that it has received the necessary regulatory approval to resume recruitment of the remaining three patients in the Phase I/IIa clinical trial of NTCELL® in Parkinson’s disease. The trial was paused in December last year while the company completed internal and external audit and regulatory processes.

Dr Ken Taylor, NTCELL Program Director and Acting Chief Executive, is pleased that patient recruitment in the clinical trial of NTCELL for Parkinson’s can resume.

“The completion of the clinical trial is an initial step in progressing NTCELL to commercialisation as the first disease modifying treatment for Parkinson’s disease.”

Existing treatments for Parkinson’s treat the symptoms rather than attempting to regenerate the affected brain cells. Many people with Parkinson’s no longer respond to these treatments.

“LCT is committed to developing and marketing NTCELL for Parkinson’s patients not responding to current therapies. We also intend to further investigate the potential of our patented cell therapy as a treatment for other neurodegenerative disorders,” said Dr Taylor.

Preclinical studies which confirmed NTCELL initiated nerve growth support the development of NTCELL as a potential treatment for other neurological diseases such as Huntington’s, Motor Neuron and Alzheimer’s.

For further information: www.lctglobal.com

About Living Cell Technologies
Living Cell Technologies (LCT) is an Australasian biotechnology company researching and developing cell therapies to treat diseases with high unmet clinical need. LCT’s lead product NTCELL® is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory producing nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration.

NTCELL is in Phase I/IIa clinical trial in New Zealand for the treatment of Parkinson’s disease. It has the potential to be used in a number of indications.

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its research and development, operations and manufacturing facilities based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter

ENDS

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

February 2017: Guns N' Roses - New Zealand Dates Announced

Founder Axl Rose and former members, Slash and Duff McKagan have regrouped for one of the century’s most anticipated tours... Rolling Stone said: "This was the real thing, the thing we'd all been waiting for: the triumphant return of one of the most important bands to cross rock music history. And it happened in our lifetime.” More>>

Werewolf: Brando, Peckinpah And Billy The Kid

Gordon Campbell: Initially, One-Eyed Jacks was supposed to have been directed by Stanley Kubrick from a script by Sam Peckinpah – yet it quickly became Brando’s baby... More>>

Book Awards: ANZAC Heroes Wins Margaret Mahy Book Of The Year

“Simply stunning, with gold-standard production values,” say the judges of the winner of this year’s Margaret Mahy Book of the Year Award in the prestigious New Zealand Book Awards for Children and Young Adults. ANZAC Heroes is also the winner of the Elsie Locke Award for the Best Book in the Non-Fiction category. More>>

Baby Animals: Hamilton Zoo Rhino Calf Named

Hamilton Zoo’s latest rhino calf has been named Samburu and he's being celebrated with a unique zoo experience... Samburu arrived after his mother Kito’s 16-month pregnancy and the calf brings the number of white rhinos at Hamilton Zoo to six. More>>

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news